Kristof Van Kolen

Kristof Van Kolen

Auto-generated profile, based on publicly available information

Kristof Van Kolen

Neuroscience Department, Janssen Research and Development, 2340 Beerse, Belgium

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2010 in Neuropharmacology
Verified
Journal Article
Closed access
KKKristof Van Kolen
Kristof Van Kolen
KVKarin Verstraeten
Karin Verstraeten
IRInes Royaux
Ines Royaux
RHRonald De Hoogt
Ronald De Hoogt
EGEric Gutknecht
Eric Gutknecht
PPPieter J. Peeters
Pieter J. Peeters

7 August 2018 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
PDF file
MVMarc Vandermeeren
Marc Vandermeeren
MBMarianne Borgers
Marianne Borgers
KKKristof Van Kolen
Kristof Van Kolen
CTClara Theunis
Clara Theunis
BVBruno Vasconcelos
Bruno Vasconcelos
MMMarc H. Mercken
Marc H. Mercken
The tau spreading hypothesis provides rationale for passive immunization with an anti-tau monoclonal antibody to block seeding by extracellular tau aggregates as a disease-modifying strategy for the treatment of Alzheimer’s disease (AD) and potential

1 July 2019 in Alzheimer's & Dementia
Verified
Journal Article
Open access
WGWendy R. Galpern
Wendy R. Galpern
MMMarc Mercken
Marc Mercken
KKKristof Van Kolen
Kristof Van Kolen
MTMaarten Timmers
Maarten Timmers
KHKatrin Haeverans
Katrin Haeverans
LNLuc Van Nueten
Luc Van Nueten

1 March 2013 in Journal of Pharmaceutical and Biomedical Analysis
Verified
Journal Article
Closed access
LDLore Delbroek
Lore Delbroek
KKKristof Van Kolen
Kristof Van Kolen
LSLiesbeth Steegmans
Liesbeth Steegmans
RCRaquel da Cunha
Raquel da Cunha
WMWim Mandemakers
Wim Mandemakers
DMDiederik W. Moechars
Diederik W. Moechars

1 September 2020 in Neurobiology of Disease
Verified
Journal Article
Open access
JDJan R. Detrez
Jan R. Detrez
IBInès R.H. Ben-Nejma
Inès R.H. Ben-Nejma
KKKristof Van Kolen
Kristof Van Kolen
DDDebby Van Dam
Debby Van Dam
PDPeter Paul De Deyn
Peter Paul De Deyn
WVWinnok H De Vos
Winnok H De Vos
Progressive accumulation of hyperphosphorylated tau is a hallmark of various neurodegenerative disorders including Alzheimer's disease. However, to date, the functional effects of tau pathology on brain network connectivity remain poorly understood. To directly interrogate the impact of tau pathology on functional brain connectivity, we conducted a longitudinal experiment in which we monitored a fibril-seeded hTau.P301L mouse model using correlative whole-brain microscopy and resting-state functional MRI. Despite a progressive aggravation of tau pathology across the brain, the major resting-state networks appeared unaffected up to 15 weeks after seeding. Targeted analyses also showed that the connectivity of regions with high levels of hyperphosphorylated tau was comparable to that observed in controls. In line with the ostensible retention of connectivity, no behavioural changes were detected between seeded and control hTau.P301L mice as determined by three different paradigms. Our data indicate that seeded tau pathology, with accumulation of tau aggregates throughout different regions of the brain, does not alter functional connectivity or behaviour in this mouse model. Additional correlative functional studies on different mouse models should help determine whether this is a generalizable trait of tauopathies.

12 November 2020 in BMC Molecular and Cell Biology
Verified
Journal Article
Open access
PDF file
AMAndré Marreiro
André Marreiro
KKKristof Van Kolen
Kristof Van Kolen
CSCristiano Sousa
Cristiano Sousa
LTLiesbet Temmerman
Liesbet Temmerman
BVBruno Vasconcelos
Bruno Vasconcelos
MMMarc H. Mercken
Marc H. Mercken
Background: Although several studies demonstrate prion-like properties of Tau fibrils, the effect of size in the seeding capacity of these aggregates is not fully understood. The aim of this study is to characterize Tau seeds by their size and seeding capacity. Methods: Tau aggregates were isolated from postmortem AD brain tissue and separated from low molecular weight species by sucrose gradient ultracentrifugation. Biochemical characterization of the different fractions was done by non-reducing Western blotting and aggregate-specific immuno-assays using in house developed anti-Tau monoclonal antibodies, including PT76 which binds to an epitope close to the microtubule-binding domain and, hence, also to K18. Seeding efficiency was then assessed in HEK293 cells expressing K18 FRET sensors. Results: We observed that upon sonication of Tau aggregates different size-distributed tau aggregates are obtained. In biochemical assays, these forms show higher signals than the non-sonicated material in some aggregation-specific Tau assays. This could be explained by an increased epitope exposure of the smaller aggregates created by the sonication. By analyzing human brain derived and recombinant (K18) Tau aggregates in a cellular FRET assay, it was observed that, in the absence of transfection reagent, sonicated aggregates showed higher aggregation induction. Preparations also showed altered profiles on native PAGE upon sonication and we could further separate different aggregate species based on their molecular weight via sucrose gradients. Conclusions: This study further elucidates the molecular properties regarding relative aggregate size and seeding efficiency of sonicated vs. non-sonicated high molecular weight Tau species. This information will provide a better knowledge on how sonication, a commonly used technique in the field of study of Tau aggregation, impacts the aggregates. In addition, the description of PT76-based aggregation specific assay is a valuable tool to quantify K18 and human AD Tau fibrils.